1977年美国食品和药物管理局(FDA)批准使用肺炎球菌14价多糖菌苗,该制品含有80%以上的肺炎球菌流行菌型。但是经进一步调查各地菌型及对各菌型间的交叉免疫进行研究后,美国最近又研制了23价肺炎球菌多糖体菌苗。为了解本菌苗的抗原性及安全性,作者于1983年5月～9月间进行了免疫试验。23价菌苗由美国Merck公司生产,批号为12535/CJ383。每个剂量含各型多糖575μg。为了减少副反应,其抗原量较14价菌苗 1977 US Food and Drug Administration (FDA) approved the use of pneumococcal 14 price polysaccharide vaccine, the product contains more than 80% of the pneumococcal strains. However, after further investigation of the bacterium types and cross-immunization among the various bacterial species, the United States recently developed a 23-valent pneumococcal polysaccharide bacterin. In order to understand the antigenicity and safety of the vaccine, the author conducted an immunization test in May-September 1983. 23 price of vaccine produced by the United States Merck, batch number 12535 / CJ383. Each dose contains 575μg polysaccharides. In order to reduce side effects, the antigen than the 14-valent vaccine